Filing summary
Registrant and period: The supplied filing is Brilliant Acquisition Corporation’s Form 10-K for the fiscal year ended December 31, 2021, filed March 31, 2022. This does not match the request metadata naming T3 Defense Inc.; investors should verify the issuer and filing before relying on this summary.
Business context
Brilliant was a Nasdaq-listed blank-check company (SPAC), incorporated in the British Virgin Islands, formed to pursue a business combination. It had no operating business or revenue through year-end and was searching for a target, with a stated focus on Asia-Pacific opportunities. Its securities traded as BRLIU, BRLI, BRLIR and BRLIW.
After year-end, on February 22, 2022, Brilliant agreed to merge with Nukkleus Inc. Under the agreement, assuming no redemptions, former Nukkleus shareholders were expected to own approximately 66% and former Brilliant shareholders approximately 34% of the combined company. The transaction was subject to conditions and was not completed as of the filing.
Financial results and liquidity
| Metric | 2021 | 2020 |
|---|---|---|
| Revenue | None | None |
| Operating costs | $670,916 | $148,010 |
| Net loss | $599,127 | $317,737 |
| Basic and diluted loss per share | $0.10 | $0.09 |
| Net cash used in operating activities | $430,914 | $137,077 |
| Cash outside trust at year-end | $283,403 | $712,817 |
| Trust account investments at year-end | $47,387,687 | $46,003,053 |
| Related-party promissory notes at year-end | $1,624,833 | $243,833 |
2021 net loss included $67,155 of income from a decline in the fair value of derivative warrant liabilities and $4,634 of trust-account interest income. The comparable 2020 warrant remeasurement was a $172,787 loss; interest income was $3,060. The company had no long-term debt or off-balance-sheet financing arrangements disclosed. Year-end current liabilities were $1,934,930, including sponsor notes; working capital deficit was $1,651,528.
The $47.4 million trust balance was restricted principally for a business combination or public-share redemptions; it was not ordinary operating cash. The company reported it expected to have sufficient cash for operations through the business-combination deadline, but the auditor highlighted substantial doubt about the company’s ability to continue as a going concern if it could not obtain funding and complete a combination by July 23, 2022.
Changes, outlook and material matters
- Net loss increased by $281,390 year over year as operating costs rose by $522,906; the more favorable warrant fair-value change partly offset the higher costs.
- Cash outside the trust fell by $429,414 during 2021. Sponsor loans funded $1,381,000 of financing cash inflows, while $1,380,000 was deposited into the trust for deadline extensions.
- The sponsor extended the combination period three times during 2021, depositing $460,000 each time. In March 2022, shareholders approved a further extension to July 23, 2022; following 633,792 share redemptions and the sponsor’s net $634,594 trust contribution, the filing reported about $41.5 million remaining in trust and approximately $10.46 per public share.
- If no combination is completed by the applicable deadline and shareholders do not approve another extension, Brilliant must cease operations and redeem public shares, subject to applicable law and creditor claims. Rights and warrants could expire worthless. Trust assets may be exposed to creditor claims, and the sponsor’s indemnification capacity was not independently verified.
- The filing reports no litigation known to management and no material legal proceedings. COVID-19 could adversely affect the search for a target, but the specific impact was not determinable.
- Management concluded disclosure controls were effective, but identified a material weakness in internal control over financial reporting related to accounting for complex warrants and redeemable shares. Remediation was planned; completion or effectiveness was not assured. The auditor did not attest to internal controls.
- Related-party sponsor notes were non-interest-bearing and generally payable upon consummation of a business combination. The company also disclosed potential transaction-advisor fees payable upon closing, including a $1.61 million fee to EarlyBirdCapital, subject to stated reductions, and a possible additional fee if it introduced the target.
Key facts for investors to verify
- Confirm the issuer: the document is Brilliant Acquisition Corporation’s 2021 Form 10-K, not a T3 Defense Inc. filing.
- Check subsequent filings for the status and terms of the proposed Nukkleus transaction, any amendments, approvals, redemptions and closing outcome.
- Verify post-extension trust cash, public shares outstanding, sponsor contributions and the then-current business-combination deadline.
- Assess the going-concern warning, the company’s limited unrestricted cash, dependence on sponsor financing and potential creditor claims against trust assets.
- Review remediation of the material weakness and any later auditor or management disclosures about financial reporting controls.
- Review dilution, redemption mechanics, sponsor interests and transaction-advisor compensation, including the potential effects of rights and warrants.